AZ/Merck & Co’s Lynparza scores huge ovarian cancer winAstraZeneca and Merck & Co’s Lynparza (olaparib) has massively reduced the risk of BRCA-mutated ovarian cancer progressing in Share XAZ/Merck & Co’s Lynparza scores huge ovarian cancer winhttps://pharmaphorum.com/news/az-merck-cos-lynparza-scores-huge-ovarian-cancer-win/
Roche’s Tecentriq posts trial wins in two key indicationsRoche has scored two big wins with its Tecentriq cancer immunotherapy at ESMO in tough to treat triple Share XRoche’s Tecentriq posts trial wins in two key indicationshttps://pharmaphorum.com/news/roches-tecentriq-posts-trial-wins-in-two-key-indications/
Can simulated datasets unlock the potential of patient data?Overview Patient level data offers the promise of insights which can craft new and better pathways, enable development Share XCan simulated datasets unlock the potential of patient data?https://pharmaphorum.com/debates-insight-patients/can-simulated-datasets-unlock-the-potential-of-patient-data/
BMS’ Opdivo+Yervoy could become first choice for certain colorectal cancer patientsBristol-Myers Squibb’s Opdivo and Yervoy combination could become first line treatment for a small group of metastatic colorectal Share XBMS’ Opdivo+Yervoy could become first choice for certain colorectal cancer patientshttps://pharmaphorum.com/news/bms-opdivoyervoy-could-become-first-choice-for-certain-colorectal-cancer-patients/
First line kidney cancer could get crowded as Merck KGaA/Pfizer join the frayCompetition in first line kidney cancer is heating up after Germany’s Merck KGaA and Pfizer briefed the ESMO Share XFirst line kidney cancer could get crowded as Merck KGaA/Pfizer join the frayhttps://pharmaphorum.com/news/first-line-kidney-cancer-inlyta-bavencio/
Clovis hopes to get ahead of rivals in prostate cancer with RubracaClovis’ PARP inhibitor drug Rubraca is showing promise in prostate cancer, according to data released at this year’s Share XClovis hopes to get ahead of rivals in prostate cancer with Rubracahttps://pharmaphorum.com/news/clovis-hopes-to-get-ahead-of-rivals-in-prostate-cancer-with-rubraca/
Novartis wants to blaze a trail in breast cancer with PIK3 drugNovartis is preparing to file its PIK3 drug combination for a certain group of breast cancer patients, after Share XNovartis wants to blaze a trail in breast cancer with PIK3 drughttps://pharmaphorum.com/news/novartis-wants-to-blaze-a-trail-in-breast-cancer-with-pik3-drug/
Merck aims for first line kidney cancer use for Keytruda comboMerck & Co is to request licences for its Keytruda immunotherapy in kidney cancer, following trial results showing Share XMerck aims for first line kidney cancer use for Keytruda combohttps://pharmaphorum.com/news/merck-aims-for-first-line-kidney-cancer-use-for-keytruda-combo/
Amgen invests £50m in UK genetics firm Oxford NanoporeBiotech giant Amgen has ploughed £50 million into a genetic sequencing company to support the development of its Share XAmgen invests £50m in UK genetics firm Oxford Nanoporehttps://pharmaphorum.com/news/amgen-invests-50m-in-uk-genetics-firm-oxford-nanopore/
